Kornimate/medical-research-clean huggingface dataset:
we talk about our hypertension

Conditions: Hypertension

Summary: the proposed pilot community-based research project will examine the feasibility, acceptability, and potential efficacy of the storytelling intervention compared with usual care in hypertension control among rural residents in 4 communities in vietnam. this is a major clinical and public health problem in this developing country.


Eligibility criteria:
inclusion criteria: consenting adult men and women must fulfill each of the following criteria: 1. be a resident of the selected commune; 2. be aged 50 years or older; 3. have a diagnosis of hypertension according to the 7th joint national commission of high blood pressure (jnc 7) 4. not be cognitively impaired (as assessed by study physicians) 5. not be a "story teller" used to develop the intervention; 6. not be a family member of another participant in the study exclusion criteria:
psychological health influences the choice of device in proximal humeral fractures

Conditions: Humeral Fracture, Proximal

Summary: it was conducted a prospective study with a series of 63 patients treated with o.r.i.f. (open reduction and internal fixation) (group a) and with rsa (reverse shoulder arthroplasty) (group b) for three and four-part proximal humeral fractures according to neer classification system. one independent observer performed clinical and a psychological evaluation at one(t0), six(t1) and twelve months(t2) postoperatively. the constant's score and the disabilities of the arm, shoulder and hand (dash score) were used for clinical evaluation, while general anxiety disorder-7 (gad-7) and caregiver strain scale (css) were used for psychological evaluation.


Eligibility criteria:
inclusion criteria: * three and four-part proximal humeral fractures according to neer classification system; * patients seventy years or older; * shoulder surgery within one week after trauma exclusion criteria: * exposed fractures; * pathological fractures; * proximal humerus fractures with metaphyseal or diaphyseal extension; * contraindications to surgery associated with organ dysfunctions or with coagulopathy; * allergy or hypersensitivity to the orthopedic implants; * patients who were unable to attend the different follow-ups; * patients with psychiatric disorders

Keywords: open reduction and fixation reverse shoulder arthroplasty
study of adg106 in combination with pd-1 antibody in advanced or metastatic solid tumors and/or non hodgkin lymphoma

Conditions: Solid Tumor; Non Hodgkin Lymphoma

Summary: this is a multicenter, open-label, phase ib/ii study of adg106 in combination with pd-1 antibody in advanced solid tumors and relapsed/refractory non-hodgkin lymphoma. the primary objective of phase ib: to evaluate the maximum tolerated dosage (mtd) of adg106 in combination with pd-1 antibody in advanced solid tumors and relapsed/refractory non-hodgkin lymphoma, and to determine the recommended phase ii clinical studies dosage (rp2d).


Eligibility criteria:
inclusion criteria: * patients with advanced solid tumors or relapses/refractory non-hodgkin's lymphoma confirmed by histology or cytology * has at least one measurable lesion (solid tumor according to recist v1.1 criteria, non-hodgkin's lymphoma according to lugnao criteria) * ecog score of 0 or 1; * expected survival time ≥ 3 months (at the discretion of the investigator); * adequate organ and bone marrow function; * voluntarily sign the informed consent form; exclusion criteria: * has central nervous system primary malignant tumor, active epileptic seizure, spinal cord compression or carcinomatous meningitis * the previous anti-tumor treatment has not passed the prescribed washout period * hiv antibody is positive, or with other acquired/congenital immunodeficiency disease, or with history of organ transplantation; * active hepatitis b or hepatitis c virus (hcv) antibody was positive; * patients who are pregnant or lactating; * known or suspected hypersensitivity to the study drug or its pharmaceutical excipients (including mono-hydrate citric acid, sodium di-hydrate citric acid, mannitol, polysorbate, arginine, succinic acid); * any active autoimmune disease, or known history of autoimmune disease, or syndrome requiring systemic steroids or immunosuppressive medications (other than controlled thyroid disease with alternative therapy/non-immunosuppressive therapy); * participation in another therapeutic or interventional clinical study in the meantime; * other circumstances where the investigator considers it is not appropriate to participate in the study.

Keywords: solid tumor and non hodgkin lymphoma
personalized radiotherapy for biochemical recurrence of prostate cancer after prostatectomy.

Conditions: Prostate Cancer

Summary: a randomized phase iii trial to study the effect of adding lymph node irradiation in patients with poor prostate-specific antigen (psa) response during salvage radiotherapy for biochemical recurrence (0.15 ≤ psa \<0.70 ng/ml) after prostatectomy.


Eligibility criteria:
inclusion criteria: * life expectancy \> 10 years * age ≥18 years. * world health organization (who) performance status 0-1. * estimated life expectancy \>10 years. * histological evidence of prostate cancer in the prostatectomy specimen * primary tumor, regional nodes, metastasis (tnm): any primary tumor (pt), pathologically node-negative (pn0), m0. * biochemical recurrence (bcr) after prostatectomy, with 0.15 ≤ psa \<0.70 ng/ml. * patients must be able to comply with the protocol. * signed informed consent. * adequate laboratory findings (haemoglobin (hb) \>90g/l, absolute neutrophil count \>1.0x109/l, platelets \>75x109/l, bilirubin \<1.5x upper limit of normal (uln), alanine aminotransferase (alat) \<5x uln and creatinine \<1.5 uln). exclusion criteria: * metastases (regional lymph nodes or distant)\* diagnosed with imaging. * prior or ongoing hormonal therapy (antiandrogens or gonadotropin releasing hormone). * prior radiotherapy to the pelvis. * prior malignancy other than prostate cancer and basalioma in the past five years. * clinically significant (i.e. active) cardiovascular disease e.g. myocardial infarction (≤6 months), unstable angina, new york heart association (nyha) class iii-iv congestive heart failure. * severe pulmonary disease. * any other serious or uncontrolled illness which in the opinion of the investigator makes it undesirable for the patient to enter the trial.

Keywords: prostate cancer prostate-specific antigen psa psa radiation lymph node radiation prostate cancer recurrence randomized trial prostatic neoplasms
single session narrative therapy study

Conditions: Mental Health Issue; HIV; Substance Use

Summary: this pilot research study will provide timely access to behavioral health services through the provision of a single-session narrative therapy intervention. the goal of this 6-month study is to test the acceptability, feasibility, and fit of the intervention in an integrated primary care clinic serving people living with hiv.

single-session interventions are designed to address barriers to engaging in care and address the issues of long waitlists and limited provider availability. offering a single session intervention soon after a referral is made is a strategy on a stepped-care continuum model that has been found to be an effective approach to manage population mental health needs. this study aims to 1) pre-pilot a single-session narrative therapy intervention with patients currently on the waitlist for psychotherapy services at an hiv primary care clinic to evaluate the acceptability of this treatment option for patients and the feasibility of proposed data collection followed by 2) a 6-month pilot study of the same intervention to evaluate intervention acceptability, fit, and impact on service and clinical outcomes. at the end of this study, patient and provider-level data on the utility of integrating a single-session psychotherapy service as part of the continuum of behavioral health services in an integrated care setting will be obtained, which the investigators can utilize to design a larger implementation-effectiveness trial.

Eligibility criteria:
patient inclusion criteria * adults (age 18 years and older) who are patients at \[blinded\] clinic * have agreed to participate in the single session intervention * ability to complete the interview and research surveys in english patient exclusion criteria: * participants with need for urgent mental health treatment (e.g., at imminent risk of suicide or harm to others; disabling symptom presentation) * inability to provide informed consent provider inclusion criteria: * adults (age 18 years and older) * referring providers at \[blinded\] clinic (social worker, primary care physician, mental health professional etc.) * ability to complete the research survey or interview in english. provider exclusion criteria: * inability to provide informed consent * non-referring providers

Keywords: brief narrative therapy implementation outcome stepped care psychotherapy integrated primary care
efficacy of transcutaneous nerve stimulation on improvement of overactive bladder symptoms

Conditions: Overactive Bladder

Summary: overactive bladder (oab) is a very common problem that impairs the quality of life of about 17% of adult population in usa above the age of 40. the issues becomes more prominent with getting older. oab was determined by international continence society as urgency (immediate desire to urinate that could not be postponed) with or without incontinence usually associated with increased frequency and nocturia (urination at night). in 2012, american urologic association published clinical guidelines for the treatment of oab of non neurogenic origin. neuromodulation was proposed as the third line of treatment and two treatments were recommended: sacral nerve neuromodulation (snm) and posterior tibial nerve stimulation (ptns). each of above mentioned procedures are invasive. snm involves lead implantation in operating room using x-ray guidance and anesthesia. ptns involves needle insertion on the low extremity. the investigators would like to examine the efficacy of transcutaneous nerve stimulation (tens) in refractory to the first two lines of oab treatment patients.


Eligibility criteria:
inclusion criteria: * male and female patients * age above 18 * oab symptoms more than 6 months before run into the study * oab symptoms refractory to medical oral and cognitive treatments * adverse events or unwillingness to continue with abovementioned treatments * patients with oab symptoms with no evidence of neuropathic nature * patients who signed informed consent fully understanding the treatment and study design exclusion criteria: * children * patients who unable or did not sign an informed consent or do not understand the study design and the treatment * patients who have implanted electric devices (eg. cardiac stimulators etc.) * patients who have post voiding residual more than 100ml * patients who have neuropathic oab or pelvic ongoing malignancy or prior pelvic radiation * patients who were treated in the last 6 months with snm, ptns or intravesical botox injections * patients with denovo oab after recent implantation of tension-free vaginal tape (tvt) procedure * stress urinary incontinence predominant complaints in mixed incontinence patients * significant pelvic organ prolapse in women or an evidence of significant bladder outlet obstruction in male patients * patients with a history of recurrent urinary tract infections (utis) during the last 2 years * any medical condition that involves skin on the lower extremity * bilateral leg amputation * any medical condition that on investigator's mind could have an adverse impact on the patient during the study * participation in a clinical study at the last 6 months

Keywords: overactive bladder transcutaneous electric stimulation posterior tibial nerve stimulation
remote-delivered mbct for scad survivors

Conditions: Acute Coronary Syndrome; Coronary Artery Disease; Anxiety; Sleep

Summary: spontaneous coronary artery dissection (scad) is an important cause of cardiac events, primarily affecting young healthy women with no cardiovascular risk factors. the 10-year recurrence rate is 30%, but scad recurrence cannot be predicted. approximately half of scad survivors struggle with significant anxiety and fear of recurrence (for), which contributes to poor sleep and physical inactivity and, thereby, increased risk of recurrence. mindfulness-based cognitive therapy (mbct) is an 8-week group intervention with evidence to improve for and health behaviors (sleep, physical activity), through psychological mechanisms that directly target key for processes (interoceptive bias, intolerance of uncertainty). i adapted mbct to target for, sleep, and physical activity in cardiac event survivors via group videoconferencing delivery (upbeat-mbct), however this intervention has not yet been targeted to scad survivors. i propose an open pilot trial to test the feasibility, acceptability, and changes in psychological and behavioral health variables in scad survivors participating in upbeat-mbct (n=16). participants will be recruited from the mgh scad program and asked to complete self-report surveys and actigraphy before and after the intervention. the primary outcomes are feasibility and acceptability of the intervention and research procedures. exploratory outcomes are changes in psychological and behavioral variables and their inter-correlations. this project would be the first and only behavioral intervention for scad survivors and would provide preliminary data for an nih stage ii efficacy trial to develop an accessible and efficacious intervention for a vulnerable group of scad survivors, with generalizability to survivors of other cardiac events.


Eligibility criteria:
inclusion criteria: * age \>18 years * cardiologist-confirmed diagnosis of scad in the past 1-12 months * english-speaking and reading * internet access (via computer or mobile device). exclusion criteria: * terminal illness with life expectancy \<1 year * severe mental illness requiring urgent psychiatric intervention (e.g., active suicidal ideation) or past-year psychiatric hospitalization) * significant cognitive impairment preventing informed consent determined by study staff or medical record review (e.g., medical history of cognitive impairment) * deemed unable to complete research procedures (e.g., group sessions or surveys) per clinical judgment of study staff * unavailable for intervention sessions (e.g., schedule conflicts)
efficacy and safety of fibrin sealant vapor heated solvent/detergent treated (fs vh s/d) for reduction of lymphatic leakage by sealing axillary lymph node dissection sites

Conditions: Breast Cancer; Lumpectomy; Mastectomy Plus Axillary Lymph Node Dissection; Lymphatic Leakage

Summary: this study will monitor the safety of fs vh s/d and will evaluate whether fs vh s/d is superior to conventional surgical procedures in the reduction of lymphatic leakage by sealing the axillary lymphatics in subjects undergoing lumpectomy and level i and ii axillary lymph node dissection with two separate incisions.


Eligibility criteria:
inclusion criteria: * written informed consent has been obtained from the subject prior to fs vh s/d administration * female subjects \>= 19 years of age * subjects with breast cancer scheduled to undergo lumpectomy of the breast and level i and ii axillary lymphadenectomy with two separate incisions exclusion criteria: * subjects with known hypersensitivity to aprotinin or other components of the product * subjects with immunodeficiency * subjects with increased red cell production (e.g., in hemolytic anemia) * subjects with coagulation disorders shown by exceeding the normal range of any of following: prothrombin time (pt), quick, activated partial thromboplastin time (aptt), fibrinogen level, or thrombocytes. * subjects having previously had axillary surgery * subjects having undergone irradiation therapy to the axillary tissue * subjects having ever received chemotherapy before the surgery

Keywords: axillary wound seroma fistulae
a 2-year prospective follow-up study of the global unite reverse fracture shoulder system for proximal humerus fractures

Conditions: Shoulder Fractures

Summary: the objective of this study is to evaluated the efficacy and safety of the reverse total shoulder prosthesis (rtsa) for complex proximal humerus fractures. the clinical results of rtsa will be compared to clinical results from a historical cohort, that received a hemiarthroplasty of the shoulder.


Eligibility criteria:
inclusion criteria: * fracture or fracture dislocation not suitable for non-operative treatment or for osteosynthesis due to displacement and comminution * patients older than 65-years of age, or younger than 65-year of age if the surgeon assesses the physiological age as older. * all patients, regardless of age, with an insufficient or irreparable rotator cuff exclusion criteria: * brachial plexus palsy * previous ipsilateral fracture of clavicula, scapula, or proximal humerus * cognitive disabilities or substance abuse enabling rehabilitation and follow-up * patients without a danish civil registration number

Keywords: humeral fractures, proximal
pregabalin vs. gabapentin on reducing opioid usage

Conditions: Analgesics; Gabapentin; Injuries; Narcotics; Pain; Trauma

Summary: this is a single-center, randomized, open-label, phase 4 clinical trial investigating the efficacy of multiple-dose administrations of pregabalin or gabapentin in combination with traditional opioid pain medications to decrease the amount of opioid pain medication usage in single-system orthopedic trauma patients.


Eligibility criteria:
inclusion criteria: 1. nurse practitioner service admissions 2. 18 years of age or older 3. patients enrolled within 36 hours of admission 4. anticipated duration of hospitalization \> 24 hours from time of consent 5. active order(s) for opioids in place at the time of enrollment exclusion criteria: 1. clinician discretion based on patient care management 2. intubated patients 3. patients with epidural 4. patients with pregabalin/gabapentin as home medications 5. patients receiving pregabalin/gabapentin upon admission 6. traumatic brain injury patients 7. crcl\<30ml/min or on hd 8. unable to take enteral medications 9. on patient controlled analgesia (pca) 10. patients with complicated wound closure 11. history of epilepsy 12. documented history of substance use disorder

Keywords: pregabalin , , gabapentin opioid pain medication use trauma opioid usage reduction
comparison of post-pinal cord injury (sci) locomotor training techniques

Conditions: Spinal Cord Injury

Summary: background: body weight supported (bws) locomotor training improves overground walking ability in individuals with motor-incomplete spinal cord injury (sci). while there are various approaches available for locomotor training, there is no consensus regarding which of these is optimal. the purpose of this ongoing investigation is to compare outcomes associated with these different training approaches. subjects and methods: subjects with chronic motor-incomplete sci have completed training and initial and final testing. subjects were randomly assigned to 1 of 4 different bws assisted-stepping groups, including: 1) treadmill training with manual assistance (tm), 2) treadmill training with stimulation (ts), 3) overground training with stimulation (og), or 4) treadmill training with robotic assistance (lr). prior to and following participation the investigators assessed: * walking-related outcome measures: overground walking speed, training speed, step length and step symmetry. * spinal cord reflex activity * electromyographic (emg) associated with walking hypotheses: in individuals with incomplete spinal cord injury (sci): 1. a 12-week period of body weight supported treadmill training with ts will produce improvements in walking function that are significantly greater than those produced by training with tm, og, lr. 2. ts training will be associated with greater changes to spinal reflex activity than will be observed in subjects trained with manual assistance or non-assisted stepping. changes to spinal reflex activation will be such that this activity more closely resembles that observed in non-disabled (nd) individuals. 3. following participation in this walking regimen, emg activity observed during walking in all groups will be more robust, more consistent and better coordinated than emg measures obtained prior to training.


Eligibility criteria:
inclusion criteria: * motor-incomplete spinal cord injury (ais c or d) * at least one year post injury * able to step with at at least one leg * able to stand from chair with no more than moderate assist of 1 person exclusion criteria: * unstable neurologic status * active orthopedic problem

Keywords: task-specific training walking locomotion function body weight support individuals with motor-incomplete spinal cord injury
renal tubular acidosis in incident renal transplant recipients

Conditions: Renal Transplant Disorder

Summary: metabolic acidosis is a common complication in incident renal transplant recipients. protracted acidosis may be associated with osteoporosis, inflammation, negative protein balance and malnutrition, and last but not least may cause renal dysfunction. preliminary data indicate an increased prevalence of nephrocalcinosis in renal transplant biopsies of incident patients presenting with metabolic acidosis. the present study aims (1)evaluate the prevalence and type of renal tubular acidosis (rta) in incident renal transplant recipients and to identify clinical correlates and (2) to find associations between rta, nephrolithiasis and nephrocalcinosis


Eligibility criteria:
inclusion criteria: * recipient of a single kidney transplant included in the protocol biopsy program. * egfr \> 30 ml/min * age ≥ 18 years * written informed consent exclusion criteria: * none

Keywords: kidney transplantation metabolic acidosis renal tubular acidosis nephrocalcinosis
the gut-lung axis in chronic obstructive pulmonary disease

Conditions: Pulmonary Disease, Chronic Obstructive; Microbiota; Immunity, Mucosal; Metabolism

Summary: patients with chronic obstructive pulmonary disease (copd) are 2-3 times more likely to occur together with chronic gastrointestinal tract (git) diseases, such as inflammatory bowel disease (ibd) or irritable bowel syndrome (ibs). similarly, despite many patients have no history of acute or chronic respiratory disease, up to 50% of ibd patients and 33% of ibs patients have pulmonary involvement, such as inflammation or impaired lung function. increasing evidence indicated chronic gut and lung disease share key conceptual features with the disorder and dysregulation of the microbial ecosystem. however, the underlying mechanisms are not well understood. our study is aimed to elucidate the intimate relationship between the gastrointestinal tract and respiratory tract, and uncover the mechanisms by which the gut microbiota affects the immune responses in the lungs, and vice versa.


Eligibility criteria:
inclusion criteria: * admitted to hospital with an exacerbation of copd; * with no history of probiotics taken; * the duration of antibiotics treatment before enrollment should be less than 72 hours. exclusion criteria: * being immunocompromised, including history of glucocorticoid taken for more than 1 month, history of immunosuppressive therapy, history of human immunodeficiency virus (hiv) infection, solid tumor or hematological malignancy; * history of long-term nursing home stays; * history of recently hospitalized (\<90 days).